Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

By BiotechDaily International staff writers
Posted on 30 Jul 2014
The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.

This notable growth will be fueled by the anticipated market entry of nine novel immunotherapies--including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations, according to Decision Resources Group (Burlington, MA, USA). Combined, Bristol-Myers Squibb’s anti-CTLA-4 agent Yervoy and innovative immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai’s MPDL-3280A and AstraZeneca/MedImmune’s MEDI4736—should dominate the immunotherapy market and capture a remarkable 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include: potential of anti-PD-1/PD-L1 agents: Interviewed experts are considerably excited about the potential of anti-PD-1/PD-L1 agents based on encouraging data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for customizing treatment fascinated interviewed experts; however, they remain watchful on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses have also been reported in patients considered to have no or low levels of PD-L1 expression.

Because of the impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), held May 30-June 3, 2014, in Chicago (IL, USA), interviewed experts expressed enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will see, according to Decision Resources Group, 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching USD 1.2 billion in 2022, these agents will not reach the commercial success of immune checkpoint inhibitors.

Decision Resources Group senior business insights analyst Khurram Nawaz, MSc, commented, “A plethora of immunotherapies are in development across a wide range of oncology indications, making this drug class one of the most exciting to watch. We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and to a lesser degree, from MPDL-3280A in non-small-cell lung cancer. Interviewed experts express mixed reactions to therapeutic vaccines and note the challenges in monitoring the efficacy of these agents. Nevertheless, they are hopeful that some vaccines will provide new therapeutic options and hold greatest promise as part of combination strategies.”

Decision Resources Group offers information and insights on critical issues within the healthcare industry.

Related Links:

Decision Resources Group



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.